Kempharm, inc (KMPH)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flows from operating activities:
Net loss

-24,522

-56,466

-43,386

-16,516

-54,664

-24,455

-5,226

Adjustments to reconcile net loss to net cash used in operating activities:
Gain on extinguishment of debt

-

2

-

-4,740

0

1,900

-

Write-off of deferred offering costs

116

-

60

445

0

-

-

Stock-based compensation expense

4,410

6,495

4,562

6,600

2,369

214

134

Non-cash interest expense

1,417

2,089

-

-

-

-

-

Non-cash interest expense

-

-

2,222

2,222

2,671

1,602

152

Amortization of debt issuance costs and debt discount

1,656

1,618

1,561

1,616

1,909

1,114

1,560

Depreciation and amortization expense

304

324

336

175

84

75

68

Fair value adjustment related to derivative and warrant liability

-1,998

-5,976

3,091

-32,465

27,276

7,223

-1,137

Change in estimated deferred offering costs

116

-

60

445

0

0

-

Loss on sublease and disposal of fixed assets

-

-

-104

-91

0

-

-

Loss on disposal of fixed assets

-

-

-

-

-

0

-

Change in assets and liabilities:
Accounts and other receivables

1,725

-

-

-

-

-

-

Prepaid expenses and other assets

-544

548

926

-2,018

1,228

-523

4

Operating lease right-of-use assets

1,537

-

-

-

-

-

-

Accounts payable and accrued expenses

-3,789

-1,635

-801

1,118

1,315

933

126

Operating lease liabilities

2,185

-

-

-

-

-

-

Other liabilities

-798

-102

77

184

0

0

-

Net cash used in operating activities

-23,737

-54,203

-33,100

-29,772

-20,268

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-14,671

-4,327

Proceeds from sale of assets

-

-

-

-

-

-

17

Purchases of property and equipment

26

21

181

643

135

47

51

Restricted cash for collateral

-

-

-

-

-

0

-

Purchases of marketable securities and long-term investments

-

-

27,378

89,849

19,002

0

-

Maturities of marketable securities

3,260

33,353

54,971

44,645

0

0

-

Net cash (used in) provided by investing activities

3,234

33,332

27,412

-45,847

-19,137

-

-

Cash flows from financing activities:
Proceeds from equity line of credit

5,446

-

-

-

-

-

-

Proceeds from at-the-market offering, net of commissions

-

4,828

-

-

-

-

-

Proceeds from underwritten public offering, net of commissions

-

23,500

-

-

-

-

-

Repayment of obligations under capital lease

-

193

157

79

32

31

53

Payment of debt and stock issuance costs

-

-

-

983

2,533

163

-

Payment of deferred offering costs

-

184

-

-

-

-

-

Repayment of principal on finance lease liabilities

207

-

-

-

-

-

-

Payment of debt issuance costs

300

-

-

-

-

-

-

Proceeds from exercise of common stock options

-

68

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-47

-34

Proceeds from issuance of debt, net of discounts and commissions

-

-

-

82,800

0

25,000

3,846

Repayment of term notes and related accrued interest

-

-

-

18,621

0

0

-

Payment of principal on convertible notes arising from capitalized interest

-

-

-

1,931

0

0

-

Payment of deferred offering costs

-

-

50

164

315

1,767

-

Proceeds from exercise of common stock options

-

-

4

141

413

0

-

Proceeds from initial public offering, net of discounts and commissions

-

-

-

0

59,892

0

-

Net cash provided by financing activities

4,939

28,019

-203

61,163

61,468

-

-

Net decrease in cash, cash equivalents and restricted cash

-15,564

7,148

-5,891

-14,456

22,063

-

-

Repayment of line of credit

-

-

-

-

-

35

5

Net cash (used in) provided by financing activities

-

-

-

-

-

23,004

3,788

Net decrease in cash and cash equivalents

-

-

-

-

-

8,286

-573

Supplemental cash flow information:
Cash paid for interest

5,362

5,539

5,717

3,289

0

-

-

Deferred offering costs included in accounts payable and accrued expenses

-

181

-

85

428

315

-

Trade date receivables

-

-

2,005

5,003

0

0

-

Conversion of preferred stock into common stock upon initial public offering

-

-

-

0

28,207

0

-

Unpaid offering costs charged to equity

-

-

-

0

3,276

0

-

Reclassification of 2013 warrants to equity

-

-

-

0

1,110

0

-

Embedded put option on Deerfield warrant

-

-

-

-

-

220

-

Issuance of Series D preferred stock as transaction fee

-

-

-

-

-

1,500

-

Deerfield Convertible Note principal and interest converted to common stock

-

-

-

-

-

4,159

-

Commitment shares issued in connection with equity line of credit included in deferred offering costs

300

-

-

-

-

-

-

Property and equipment financed under a lease agreement

-

52

-

-

-

-

-

Property and equipment financed under a lease agreement

-

-

284

867

0

0

94

Cash paid for interest

-

-

-

-

-

3

5

Transfer of warrants to equity upon exercise

-

-

-

755

4,293

0

-

Property and equipment included in accounts payable and accrued expenses

4

-

3

281

0

0

-

Conversion feature on 2013 convertible notes and put option

-

-

-

-

-

-

1,150

Issuance of 2013 warrants and Deerfield warrant

-

-

-

-

-

7,610

410

Conversion from Deerfield Convertible Note to Common Stock [Member]
Deerfield Convertible Note principal and interest converted to common stock

-

3,502

-

-

-

-

-

The 2021 Notes Converted to Preferred Stock [Member]
2021 Notes principal converted to preferred stock

1,537

9,577

-

-

-

-

-

The 2021 Notes Converted to Common Stock [Member]
2019 Notes principal converted to common stock

1,463

-

-

-

-

-

-

The 2019 Notes Converted to Common Stock [Member]
2021 Notes principal converted to preferred stock

1,200

-

-

-

-

-

-